Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
- 1 November 2002
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 61 (Supplement), 2ii-7
- https://doi.org/10.1136/ard.61.suppl_2.ii2
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialThe Lancet, 2002
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- Clinical guidelines: Developing guidelinesBMJ, 1999
- EtanerceptDrugs, 1999
- Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonistArthritis & Rheumatism, 1998
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- ANTI-TUMOR NECROSIS FACTOR-α MONOCLONAL ANTIBODY THERAPY FOR RHEUMATOID ARTHRITISRheumatic Disease Clinics of North America, 1998
- Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.1996
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993